COA ↓

Product

COA Doc

SYN-2624

99.1% Purity SYN-2624 Research Grade HPLC Verified

Epithalon (Epitalon)

Tetrapeptide Pineal Bioregulator · Research Grade

Select Strength — 10mg

$65.00

C₁₄H₂₂N₄O₉ MW: 390.34 g/mol CAS: 307297-39-8

Out of Stock

Notify me when back in stock

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

HPLC Purity

Lot Number SYN-2624-EPITH

Test Date

Labeled 99.1%

Actual 99.1%

HPLC Purity

Lot Number SYN-2523-EPITH

Test Date

Labeled 99.1%

Actual 99.4%

Research Data

KEY FINDINGS

🧬

33%

Mortality Reduction (15-yr Study)

All-cause mortality reduction vs. controls — Khavinson et al., 2003

🔬

TERT

Telomerase Activation

Directly activates telomerase reverse transcriptase in somatic cell cultures

✅

99.1%

HPLC-Verified Purity

Current batch SYN-2624, third-party accredited lab

❄️

36mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere — extended stability

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🧬 Telomerase Activation

TERT Upregulation in Somatic Cells

Khavinson et al. demonstrated that Epithalon directly upregulates TERT expression in somatic cell cultures including fibroblasts and retinal epithelial cells, extending telomere length and delaying replicative senescence — the first peptide shown to activate telomerase in non-cancerous human cells.

🔬 2.4× TERT upregulation + 18% telomere length extension — first peptide to activate telomerase in non-cancerous somatic cells.

PMID 14523363 — Neuroendocrinol. Lett.

📈 15-Year Mortality Study

33% Mortality Reduction — Longest Peptide Clinical Follow-Up

The 15-year follow-up study remains the longest prospective human dataset for any synthetic peptide. Periodic Epithalon administration (20 μg/kg over course cycles) produced 33% all-cause mortality reduction, improved immune markers, sustained melatonin production, and reduced cancer incidence vs. untreated elderly controls.

🔬 33% all-cause mortality reduction in 15-year follow-up — the most comprehensive longevity dataset for any synthetic peptide.

PMID 14523363 — Neuroendocrinol. Lett.

33 %

15-Year Follow-Up — 33% Mortality Reduction

Epithalon is a tetrapeptide pineal bioregulator developed at the St. Petersburg Institute of Bioregulation. A 15-year follow-up study published in Neuroendocrinology Letters demonstrated 33% reduction in all-cause mortality vs. untreated controls in an elderly cohort — alongside documented telomerase activation and melatonin restoration.

15-Year Mortality Follow-Up — Epithalon vs. Control

Mortality (Epithalon cohort) −33%

Mortality (Control cohort) 0%

Source: Khavinson VKh et al., Neuroendocrinol. Lett., 2003

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2624-EPITH

Specification	Value
CAS Number	307297-39-8
Molecular Formula	C₁₄H₂₂N₄O₉
Molecular Weight	390.34 g/mol
Purity (HPLC)	99.1%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	36 months from production date
Research Grade	Yes — For In Vitro Use Only

33 %

All-Cause Mortality Reduction vs. Control Cohort (15-Year Follow-Up)

Epithalon cohort −33%

Control cohort 0%

Comparative Activity Profile

Epithalon

Observed Adverse Indicators

Transient injection-site erythema

low

Mild fatigue (short-term)

low

Serious adverse events reported

low

Pro-neoplastic effects observed

low

⚠️ Theoretical Concern

Research Context & Long-Term Safety Data

Epithalon is one of the most extensively studied research peptides in terms of longitudinal follow-up, with a 15-year mortality cohort study and multiple shorter-term trials available through the St. Petersburg Institute of Bioregulation.

15-year human prospective cohort — no serious adverse events; 33% all-cause mortality reduction
Pineal-derived tetrapeptide (Ala-Glu-Asp-Gly) — not a novel synthetic xenobiotic compound
Anti-neoplastic activity in multiple animal tumour models — no pro-neoplastic effects observed in any study
For in vitro laboratory research use only — not for human or veterinary administration

Epithalon (Epitalon)

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

TERT Upregulation in Somatic Cells

33% Mortality Reduction — Longest Peptide Clinical Follow-Up

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Research Context & Long-Term Safety Data

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS